Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004196 · ClinicalTrials.gov registry record · Phase 3
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
A Phase 3 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
NCT00004196 is a Phase 3 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 3,000 participants.
The verdict
NCT00004196, a Phase 3 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node metastasis.
Interventions
- BIOLOGICAL recombinant interferon alfa
- PROCEDURE lymphangiography
- DRUG Observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 1999-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004196
The ClinicalTrials.gov registry entry for NCT00004196 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which recombinant interferon alfa is the first listed.
NCT00004196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004196 about?
NCT00004196 is a clinical study titled "Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis". RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node metastasis.
What is the current status of trial NCT00004196?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants. The study started on 1999-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00004196?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), lymphangiography (PROCEDURE), Observation (DRUG).
Who is sponsoring clinical trial NCT00004196?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.